Catalyst
Slingshot members are tracking this event:
Enrollment for ALXN1210 Phase 3 SWITCH study on Paroxysmal nocturnal hemoglobinuria (PNH) set to begin in Q2 of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALXN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 06, 2017
Occurred Source:
http://news.alexionpharma.com/press-release/company-news/fda-grants-orphan-drug-designation-alxn1210-treatment-patients-paroxysmal
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Paroxysmal Nocturnal Hemoglobinuria, Switch Trials, Alxn1210
